课题基金 / 基金详情

KaliDerm Therapeutics: A research/commercialization plan to validate, better define and add value to our proprietary dual KLK5/7 inhibitor as a novel topical therapeutic for Netherton Syndrome.

KaliDerm Therapeutics: A research/commercialization plan to validate, better define and add value to our proprietary dual KLK5/7 inhibitor as a novel topical therapeutic for Netherton Syndrome.
KaliDerm Therapeutics:一项研究/商业化计划,旨在验证、更好地定义我们专有的双 KLK5/7 抑制剂并为其增加价值,作为 Netherton 综合征的新型局部治疗剂。
批准号:
462430
负责人:
Diamandis Eleftherios P
金额:
$24.52万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-03-01 至 2024-03-01

项目摘要

项目成果

Diamandis Eleftherios P的其他基金

相关文献

中文摘要
翻译
外表皮含有几种蛋白水解酶,它们共同协调重要的皮肤功能,如皮肤更新、屏障功能和先天免疫。其中,来自遗传和生化研究的证据特别强调了两个问题
英文摘要
Outer epidermis contains several proteases which collectively orchestrate vital skin functions, such as skin renewal, barrier function and innate immunity. Amongst them, evidence from genetic and biochemical studies have highlighted specifically two prote
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrative PersonalizedRiskand Therapy Stratification of Localized Prostate Cancer
  • 批准号:
    388062
  • 项目类别:
    Operating Grants
  • 资助金额:
    $32.78万
  • 财政年份:
    2018
  • 负责人:
    Diamandis Eleftherios P
  • 依托单位:
Netherton Syndrome: From mechanism to therapies.
  • 批准号:
    331997
  • 项目类别:
    Operating Grants
  • 资助金额:
    $5.15万
  • 财政年份:
    2015
  • 负责人:
    Diamandis Eleftherios P
  • 依托单位:
Validation of two novel pancreatic cancer biomarkers: CUZD1 and LAMC2
  • 批准号:
    279678
  • 项目类别:
    Operating Grants
  • 资助金额:
    $37.86万
  • 财政年份:
    2013
  • 负责人:
    Diamandis Eleftherios P
  • 依托单位:
Integrated Approach to Discover Prostate Cancer Biomarkers in Seminal Plasma
  • 批准号:
    265566
  • 项目类别:
    Operating Grants
  • 资助金额:
    $30.4万
  • 财政年份:
    2012
  • 负责人:
    Diamandis Eleftherios P
  • 依托单位: